IRIS
TANDA, ENRICA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 840
Totale 840
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 840
Totale 840
Salva come PNG Salva come JPEG
Città #
Genova 279
Genoa 274
Rapallo 172
Vado Ligure 108
Bordighera 7
Totale 840
Salva come PNG Salva come JPEG
Nome #
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 144
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 76
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 68
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 61
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 60
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 50
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 40
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 37
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 36
How to make immunotherapy an effective therapeutic choice for uveal melanoma 34
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 30
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 27
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 24
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 22
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 15
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 14
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 14
Primary endobronchial melanoma: a case report and clinical management indications 14
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 13
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 12
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 11
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 10
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 9
The treatment of advanced melanoma: Current approaches and new challenges 9
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 6
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 6
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 5
Current status and perspectives in immunotherapy for metastatic melanoma 5
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms 5
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 5
The adjuvant treatment revolution for high-risk melanoma patients 5
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 4
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 4
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 4
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 4
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 3
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 3
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 3
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 2
Totale 894
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.019
article - articoli 4.999
book - libri 0
conference - conferenze 20
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202051 0 0 1 1 4 5 4 2 9 13 12 0
2020/202193 5 3 9 0 4 15 13 7 10 12 14 1
2021/2022104 11 1 3 10 5 5 2 19 6 23 3 16
2022/2023208 15 20 2 12 42 24 0 18 29 1 37 8
2023/2024246 8 12 9 28 14 50 14 7 12 20 11 61
2024/2025143 56 76 11 0 0 0 0 0 0 0 0 0
Totale 894